Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major...
Graphy Hosts ‘SMA Legends Symposium 2026’… Spotlight on Digital Orthodontics
Global orthodontic experts gather to present SMA-based clinical strategies and accelerate the adoption of next-generation digital orthodontic solutions. Global Symposium: Expanding Clinical Exchange Across 15 Countries The symposium brought together around 300 participants from 15 countries, serving as a global platform for academic exchange. World-Class Speakers: Defining...
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
- Mr. James brings more than 20 years of biopharmaceutical leadership experience, with deep expertise in capital markets, investor relations, and corporate strategy, serving in senior executive roles at Acceleron Pharma prior to its $11.5 billion acquisition by Merck and at Viridian Therapeutics - BOSTON, March 19, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering...
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved its Investigational New Drug (IND) application to initiate a Phase II clinical trial of RAG-01 for the treatment of Non-Muscle Invasive Bladder...
ACOH 2026 Early Bird Rate Ends 30 April; Abstract Submission Closes 1 April
KUCHING, Malaysia, March 19, 2026 /PRNewswire/ -- Asia's leading platform on workplace health and safety, the 24th Asian Congress on Occupational Health (ACOH) 2026, is calling on researchers, practitioners, and industry professionals to secure their participation as key deadlines approach. Scheduled to take place from 5 to 8 August at the Borneo Convention Centre Kuching, the congress serves as...
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March 20 at 8:30 a.m. HKT / March 19 at 8:30 p.m....
Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved in Macao, China
SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patients with moderate to severe hemophilia B (congenital coagulation factor IX deficiency). This product is developed and manufactured by BBM,...
Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global...
Infinitus Showcases Innovations at FHE2026, demonstrating supportive role of complex Polysaccharides on immune health
GUANGZHOU, China, March 18, 2026 /PRNewswire/ -- Infinitus (China) Company Ltd., a company with more than three decades in the traditional Chinese herbal health industry, was invited to participate in the Boao Food for Health Science Conference and Expo (FHE) 2026. During the event held at the Boao Forum for Asia International Conference Center in Hainan from March...
Allianz Partners Australia’s 2025 State of Student Healthcare Report Unpacks the Complex Realities of International Students
BRISBANE, Australia, March 19, 2026 /PRNewswire/ -- Allianz Partners Australia's 2025 State of Student Healthcare (SOSH) Report, released today, continues to track the health, wellbeing and experiences of international students in Australia. While the latest data reveals cost of living pressures and other challenges remain, it also highlights international students' grit to...
